Trials / Completed
CompletedNCT02388919
Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0303）
A Registered Randomized, Double-Blind, Placebo-Controlled (2:1), Multi-Centered Clinical Trial of Anlotinib as a Treatment for Advanced Non-Small Cell Lung Cancer
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 439 (actual)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Evaluate the efficacy and safety of Anlotinib as the 3-line treatment of patients with advanced non-small lung cancer, with placebo control.
Detailed description
Anlotinib (AL3818) is a kind of innovative medicines approved by State Food and Drug Administration（SFDA:2011L00661） which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. Anlotinib is a kinase inhibitor of receptor tyrosine with multi-targets, especially for VEGFR1、VEGFR2、VEGFR3、FGFR1/2/3、PDGFRa/β c-Kit and MET.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anlotinib | Basic dosage, take once when limosis in the morning. If patients cannot suffer from AEs, they can get declined dosage. |
| DRUG | Placebo | Basic dosage, take once when limosis in the morning. |
Timeline
- Start date
- 2015-02-26
- Primary completion
- 2017-01-05
- Completion
- 2017-01-06
- First posted
- 2015-03-17
- Last updated
- 2017-09-18
Locations
40 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02388919. Inclusion in this directory is not an endorsement.